Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06784323 · ClinicalTrials.gov registry record · NA
Tailored Anti-Inflammatory (A-I) Diet for Americans With Ulcerative Colitis (UC)
A NA study of Ulcerative Colitis, sponsored by University of Miami.
- Recruiting
- Registry status
- NA
- Development phase
- 122
- Enrollment target
- 1
- Study location
NCT06784323: Recruiting NA study of Ulcerative Colitis, sponsored by University of Miami.
NCT06784323 is a NA study of Ulcerative Colitis that is actively recruiting participants, run by University of Miami. The registered enrollment target is 122 participants, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06784323, a NA study of Ulcerative Colitis, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- NA
- Development phase
- 122 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the effect of an anti-inflammatory diet that incorporates native foods of the American diet on disease remission in American patients with Ulcerative Colitis (UC) and to identify biomarkers of response to dietary therapy.
Primary Outcome
Will be measured with SCCAI.
Conditions Studied
Interventions
- BEHAVIORAL Catered diet
- BEHAVIORAL Diet guidance sessions
- BEHAVIORAL Dietary counseling
- BEHAVIORAL Feedback sessions
Study Locations (1)
Florida
- University of Miami Health System - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2030-09-01 |
| Phase | NA |
What NCT06784323 shows while recruiting
NCT06784323 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 4 interventions - of which Catered diet is the first listed.
NCT06784323 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06784323 about?
NCT06784323 is a clinical study titled "Tailored Anti-Inflammatory (A-I) Diet for Americans With Ulcerative Colitis (UC)". The purpose of this study is to test the effect of an anti-inflammatory diet that incorporates native foods of the American diet on disease remission in American patients with Ulcerative Colitis (UC) and to identify biomarkers of response to dietary therapy.
What is the current status of trial NCT06784323?
This trial is currently recruiting. It is a NA study. The enrollment target is 122 participants. The study started on 2025-03-05. Estimated completion is 2030-09-01.
What conditions does trial NCT06784323 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT06784323?
The interventions under investigation include: Catered diet (BEHAVIORAL), Diet guidance sessions (BEHAVIORAL), Dietary counseling (BEHAVIORAL), Feedback sessions (BEHAVIORAL).
Who is sponsoring clinical trial NCT06784323?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06784323 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06784323's enrollment target sits among peer trials
122 59th of 122 higher than 63 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis
RECRUITING · NA
-
Nicotinamide Riboside in Ulcerative Colitis
RECRUITING · NA
-
Fermented Food-Supplemented Diet in Ulcerative Colitis
RECRUITING · NA
-
Impact of Prebiotics in Ulcerative Colitis
RECRUITING · NA
-
BOOM-IBD2 Pivotal Clinical Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI